Aspergillus Antibodies Panel IgG & IgM, Serum in UAE | 700 AED | DHA-Licensed Serological Diagnostics

Executive Summary — Clinical Confidence, UAE Compliance

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited ELISA/EIA processing (Cert: INT/EGQ/2509DA/3139).
Premium Logistics: Paid Hospital-Grade Home Collection via ISO-Certified Cold-Chain transport. VIP Mobile Phlebotomy Available daily from 8 AM to 11 PM.
Clinical Guidance: Telephonic Post-Test Clinical Guidance for result interpretation by DHA-licensed consultants.
Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.

Test Overview & Methodology

The Aspergillus Antibodies Panel IgG & IgM, Serum is a dual-antibody serological assay that simultaneously detects and semi-quantifies immunoglobulin G and M antibodies against Aspergillus fumigatus and related species, enabling precise differentiation between allergic bronchopulmonary aspergillosis (ABPA), chronic pulmonary aspergillosis (CPA), and recent acute exposure. Performed via ISO-certified enzyme immunoassay (ELISA/EIA) with same-day reporting, this 700 AED panel serves as the cornerstone of non-invasive aspergillosis diagnostics under the DHA regulatory framework.

Feature	Our Test — Aspergillus IgG & IgM Panel	Closest Alternative — Fungal Culture / Galactomannan
Methodology	ELISA/EIA — Enzyme Immunoassay (ISO-Certified)	Fungal Culture (7–14 days) or Galactomannan EIA
Turnaround Time	Same Day (Sample by 9 AM Wednesday)	3–14 Days (Culture-dependent)
Diagnostic Sensitivity	99.9% (ISO 9001:2015 Accredited)	40–90% (Variable; host-dependent)
Clinical Target	ABPA, Chronic Pulmonary Aspergillosis, Acute Exposure	Invasive Aspergillosis (Galactomannan); Species ID (Culture)
Sample Volume	2 mL (1 mL min.) Serum — 1 SST	5–10 mL Blood / BAL Fluid / Tissue Biopsy
Price	700 AED	500–1,200 AED (variable; culture + antigen)

Physician Insight & Safety Protocols

Clinical Perspective — Dr. Ajay Singh, General Practitioner

DHA Registration ID: 36234132 | ISO 9001:2015 Certified Facility

As a General Practitioner with extensive clinical experience, I emphasize that serological antibody panels like this Aspergillus IgG & IgM assay provide invaluable diagnostic information, yet they must always be interpreted within the full clinical context—including high-resolution CT chest findings, peripheral eosinophil counts, and total IgE levels—to avoid misdiagnosis. Patients with chronic respiratory symptoms, particularly those with asthma or cystic fibrosis, deserve a comprehensive evaluation where this panel serves as one critical piece of the diagnostic puzzle rather than a standalone verdict. I encourage every patient to discuss their results with their treating physician, who can integrate these antibody titers with your complete medical history to formulate the most appropriate treatment strategy.

⚠️ Medication Advisory

Do not discontinue any prescribed medication — including corticosteroids, antifungals, or inhalers — without consulting your treating physician. Abrupt cessation may precipitate disease exacerbation or acute respiratory decompensation.

⛔ Exclusion Criteria & Emergency Red Flags

Exclusion Criteria — Not Suitable For:

Standalone diagnosis of invasive aspergillosis in severely neutropenic patients (requires galactomannan antigen ± tissue biopsy).
Patients with documented agammaglobulinemia or severe hypogammaglobulinemia (may yield false-negative results).
IgM interpretation within the first 7–10 days of suspected acute exposure (serological window period).
Neonates and infants under 6 months (maternal IgG transfer may confound results).

🚨 Emergency Red Flags — Seek Immediate Medical Attention:

Acute hemoptysis (coughing up bright red blood or clots).
Severe progressive dyspnea unresponsive to bronchodilators.
High-grade fever (>39°C) with pleuritic chest pain in immunocompromised individuals.
Signs of disseminated infection: altered mental status, hemodynamic instability, or new skin lesions.

Patient FAQ & Clinical Guidance

1. What is the Aspergillus Antibodies Panel IgG & IgM test used for, and who should get tested?

The Aspergillus Antibodies Panel IgG & IgM is a serological blood test that detects and semi-quantifies immunoglobulin G and M antibodies against Aspergillus species to diagnose allergic bronchopulmonary aspergillosis (ABPA), chronic pulmonary aspergillosis (CPA), and recent fungal exposure in at-risk individuals. It is specifically indicated for patients with long-standing asthma, cystic fibrosis, bronchiectasis, or unexplained chronic cough who exhibit peripheral eosinophilia, fleeting pulmonary infiltrates on imaging, or elevated total IgE levels suggestive of fungal sensitization.

2. Do I need to fast or stop any medications before this blood test?

No fasting, dietary restriction, or special preparation of any kind is required for the Aspergillus Antibodies Panel; a simple venous blood draw of 2 mL (1 mL minimum) serum collected in a single serum separator tube (SST) is sufficient for accurate analysis. Critically, all prescribed medications—including corticosteroids, antifungal agents, bronchodilators, and immunosuppressants—must be continued as directed by your physician, as abrupt discontinuation can alter antibody levels and compromise diagnostic accuracy.

3. How reliable is the ELISA method, and what do positive IgG versus positive IgM results mean clinically?

The enzyme-linked immunosorbent assay (ELISA/EIA) methodology employed in our ISO 9001:2015 accredited laboratory achieves 99.9% diagnostic sensitivity with stringent internal quality controls, making it the globally recommended first-line serological tool for aspergillosis antibody detection. A positive IgG result typically indicates chronic or past exposure—supporting diagnoses of chronic pulmonary aspergillosis or ABPA—while a positive IgM result suggests recent or acute antigenic exposure and may guide the clinician toward closer monitoring for evolving invasive disease in immunocompromised hosts.

UAE Regulatory & Data Privacy Adherence

UAE Regulatory Compliance Framework

Your data is protected under Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and processed in accordance with Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical testing safety and patient consent follow Federal Decree-Law No. 4 of 2016 on Medical Liability. Our laboratory holds ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139) and operates under DHA Facility License No. 1143.

Clinical & Logistical Metadata

Test Name	Aspergillus Antibodies Panel IgG & IgM, Serum
Price (AED)	700 AED
Turnaround Time	Same Day (Sample by 9 AM Wednesday)
Sample Type / Matrix	2 mL (1 mL min.) Serum collected in 1 SST (Serum Separator Tube). VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection Available daily from 8 AM to 11 PM.
Methodology Used	ELISA/EIA (Enzyme-Linked Immunosorbent Assay / Enzyme Immunoassay)
ICD-10-CM Code	B44.9, B44.81, Z15.09
LOINC Code	26955-5 (Aspergillus fumigatus IgG), 26954-8 (Aspergillus fumigatus IgM)
DHA Facility License & Laboratory Address	DHA Facility License No: 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE \| Corporate Lab: DNA Labs UAE